Construction & Building Materials

Heidelbergcement

Price EUR66.26

Bloomberg Reuters 12-month High / Market Cap (EUI Ev (BG Estimate: Avg. 6m daily vo 3y EPS CAGR	HEI GY HEIG.F 77.0 / 60.1 12,451 19,304 671.9 38.3%			
	1 M	3 M	6 M 31	/12/15
Absolute perf.	3.2%	-6.5%	-5.6%	-12.4%
Cons & Mat	-0.6%	-8.9%	-11.9%	-10.1%
DJ Stoxx 600	-2.4%	-12.9%	-16.7%	-12.0%
YEnd Dec. (EURm)	2014	2015e	2016 e	2017e
Sales	12,614	13,373	17,703	19,110
% change		6.0%	32.4%	8.0%
EBITDA	2,117	2,371	3,356	3,884
EBIT	1,424	1,621	2,206	2,734
% change		13.9%	36.1%	23.9%
Net income	498.4	689.8	960.2	1,392
% change		38.4%	39.2%	45.0%
	2014	2015e	2016e	2017e
Operating margin	11.3	12.1	12.5	14.3
Net margin	5.5	6.9	6.5	8.6
ROE	3.8	5.1	6.5	8.9
ROCE	6.4	5.3	5.9	7.4
Gearing	48.6	35.2	51.9	43.7
(EUR)	2014	2015e	2016 e	2017e
EPS	2.66	3.68	4.85	7.03
% change	-	38.4%	31.8%	45.0%
P/E	24.9x	18.0x	13.7x	9.4x
FCF yield (%)	5.3%	5.8%	9.4%	10.2%
Dividends (EUR)	0.75	1.10	1.50	2.80
Div yield (%)	1.1%	1.7%	2.3%	4.2%
EV/Sales	1.7x	1.4x	1.3x	1.2x
EV/EBITDA	10.1x	8.1x	6.9x	5.7x
EV/EBIT	15.0x	11.9x	10.5x	8.1x



Q4 2015 EBITDA 7% above consensus. Positive outlook in key zones. ITC deal on track.

Fair Value EUR86 (+30%)

BUY-Top Picks

HeidelbergCement has published 2015 revenues at EUR13.465bn, in line with the consensus, up 6.7% (-0.2% I-f-I), with cement volumes almost flat (-0.9% o/w -0.3% in Q4). 2015 EBITDA stood at EUR2.613bn (2% above consensus but 7% above Q4 2015 estimates only), up 14.2% (8.2% I-f-I). Margin was 19.4%, up 130bp y/y. Positive outlook for key markets (US, Western Europe, Indonesia). EUR400m Italcementi deal synergies confirmed. Ongoing anti-trust discussions in the US and Europe.

ANALYSIS

- Most of the geographical zones were in line with or slightly above expectations, except Asia-Pacific (27% of EBITDA), where revenues were down 5.6% I-f-I and EBITDA margin down 50bps at 25.9%.
- North America (31% of EBITDA) remained very strong, with good momentum in Q4. Revenues increased by 6.7% for the FY and by 9.6% in Q4, with ongoing EBITDA margin improvement (+210bps for the FY). Cement volumes were healthy with a 4.6% increase in Q4 and 1.9% for the FY).
- Europe was resilient, both in western Europe (thanks positive trends in the UK) and in eastern
 Europe thanks to Poland, Czech Republic and Romania, whereas Russia and Ukraine were difficult.
 EBITDA margin improved by 200bps to 16% in western Europe whereas it fell by 60bp to 18.9% in
 eastern Europe. However, eastern European EBITDA only accounts for 8% of consolidated EBITDA,
 vs 25% for western Europe.
- Outlook: North America is expected to perform well in 2016, thanks to dynamism in the construction sector. Positive comments concerned western Europe as well, thanks to a solid UK sector in particular. Eastern Europe contries are set to benefit from the EU infra programme. Heidelberg expects good trends in Indionesia thanks to higher infrastructure investments.

Preliminary figures

EURm			I-f-I %	I-f-I %
Revenues	Q4 15	FY 15	Q4 15	FY 15
Western & Northern Europe	1074	4196	-0.6	0.1
Eastern Europe-Central Asia	248	1097	1.8	1.1
North America	943	3746	9.6	6.7
Asia-Pacific	716	2775	-8.9	-5.6
Africa-Mediterranean Basin	244	1008	5.6	11.4
Group Services	270	1060	-	-
Reconciliation	-106	-417	-	-
Total	3389	13465	-2.0	-0.2
EBITDA	Q4 15	FY 15	Q4 15	FY 15
Western & Northern Europe	192	672	25.8	17.3
Eastern Europe-Central Asia	49	207	25.9	-4.4
North America	214	829	25.0	19.5
Asia-Pacific	188	719	-16.1	-8.1
Africa-Mediterranean Basin	68	260	29.9	23.9
Group Services	7	25	-	-
Eliminations	-22	-99	-	-
Total	696	2613	10.5	8.2

Source: Company Data; Bryan Garnier & Co. ests.

VALUATION

• EUR86 FV derived from the application of historical multiples to our 2017 figures.

NEXT CATALYSTS

- Conference call at 1.30pm today
- Complete consolidated results to be published on 17th March 2016.

Click here to download document



Analyst:
Eric Lemarié
33(0) 1.70.36.57.17
elemarie@bryangarnier.com

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY

Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

NEUTRAL

Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

SELL

Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 62.7%

NEUTRAL ratings 28.4%

SELL ratings 9%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement		
7	Research agreement		
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	
11	Analyst has short position	Analyst has short position The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	
12	Analyst has long position	Analyst has long position The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	
13	Bryan Garnier executive is an officer A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.		No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No
		1	

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudential et de	2	FINMA	
(FCA)	resolution (ACPR)			

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report. Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.